Home > News > Headline News > Archive

Click on title to read the full article.

Bad Neighbors

December 26, 2009

By Laura Beil, Cure Today Magazine

Stephen Paget had a question: When cancer breaks free and starts to spread, where does it go and how does it get there? As a surgeon at the West London hospital, he knew most people didn’t die from their original tumors, but from metastatic outposts in other parts of the body.

Follow-up Presented of Nexavar® plus Taxol® Study for Treatment of Advanced Breast Cancer

December 20, 2009

By Cancer Consultants

Researchers involved in an international randomized Phase IIB study have reported that the combination of Nexavar® (sorafenib) and Taxol® (paclitaxel) improves progression-free survival (PFS) compared with Taxol plus placebo in patients with advanced or metastatic HER2-negative breast cancer. These results were presented at the 2009 San Antonio Breast Cancer Symposium.

Stereotactic Radiosurgery Preferred for Brain Metastases

December 19, 2009

By MD Anderson Cancer Center, University of Texas

Cancer Newsline - Fall 2009

Less Risk of Developing Learning, Memory Problems

Cancer patients who receive stereotactic radiosurgery (SRS) and whole brain radiation therapy (WBRT) to treat 1-3 metastatic brain tumors have more than twice the risk of developing learning and memory problems than those treated with SRS alone.

Updated Study Results Show Survival Benefit in Advanced Breast Cancer from Adding Tykerb® to Herceptin®

December 18, 2009

By Cancer Consultants

Researchers affiliated with the EGF104900 trial have confirmed that the combination of Tykerb® (lapatinib) and Herceptin® (trastuzumab) is more effective than Tykerb alone in women with HER2-positive, metastatic breast cancer that has progressed during treatment with Herceptin.

Tumors in Women with Breast Cancer Shrunk with Use of T-DM1

December 17, 2009

By Ketan Mukherjee, TopNews

A new targeted cancer medicine, T-DM1, has shown the potential to shrink tumors in women suffering from metastatic breast cancer, after all 7 popular drugs, including Herceptin, failed.

Addition of Avastin® to Chemotherapy Delays Breast Cancer Progression

December 17, 2009

By Cancer Consultants

According to the results of two Phase III clinical trials, the addition of Avastin® (bevacizumab) to first- or second-line chemotherapy delays cancer progression but may not improve overall survival among women with advanced breast cancer.

Higher Dose of Faslodex® May Delay Breast Cancer Progression

December 16, 2009

By Cancer Consultants

Researchers affiliated with the CONFIRM (Comparison of Fulvestrant in Recurrent or Metastatic Breast Cancer) trial have reported that high-dose Faslodex® (fulvestrant) significantly improves time to cancer progression compared with standard-dose Fasoldex as initial therapy for hormone-positive, advanced breast cancer. These results were presented at the 2009 San Antonio Breast Cancer Symposium.

Targeted Breast Cancer Drug Shrinks Tumors

December 15, 2009

By Charlene Laino, WebMD Health News

A new targeted cancer drug has been shown to shrink tumors in women with metastatic breast cancer after an average of seven other drugs, including Herceptin, failed.

SABCS: Novel Form of Trastuzumab Works in Refractory Metastatic Breast CA

December 15, 2009

By Crystal Phend, Senior Staff Writer, MedPage Today

SAN ANTONIO — A novel form of trastuzumab (Herceptin) with a chemotherapy-like conjugate attached appears to substantially improve outcomes in heavily-pretreated metastatic breast cancer, researchers said.

Docetaxel Plus Capecitabine Shows More Benefit as First-Line Therapy for Metastatic Breast Cancer Than Docetaxel Plus Epirubicin

December 13, 2009

By Jennifer Reising

SAN ANTONIO, Tex:  The combination of docetaxel and capecitabine is associated with an increased nonprogression rate at 6 months and a longer progression-free survival (PFS) and overall survival (OS) than docetaxel plus epirubicin as a first-line treatment for metastatic breast cancer, according to the final results of a study presented here on December 11 at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS).

 1 2 >